Celsion CORP CLSN Income Statement

Celsion corp (CLSN)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Technology development and licensing revenue
125	125	125	125	125	125	125	125	125	-	-	125	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Licensing revenue
-	-	-	-	-	-	-	-	-	-	-	-	125	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Licensing revenue
-	-	-	-	-	-	-	-	-	-	125	-	-	125	125	125	125	125	125	125	125	125	125	125	125	125	125	125	125	-	-	-	-	0	0	0	2,000	0	0
Operating expenses:
Research and development
3,052	3,065	3,674	3,558	2,767	2,343	2,187	4,593	2,741	2,905	3,348	3,348	3,475	3,620	4,225	3,336	3,441	3,702	2,883	3,567	4,506	4,281	4,629	3,165	2,893	1,869	2,269	2,022	3,203	3,425	3,539	4,112	4,693	5,136	5,414	4,964	4,348	3,951	3,439
General and administrative
1,838	1,807	1,838	2,136	2,217	2,531	1,959	3,542	1,665	2,073	1,174	1,174	1,468	1,638	1,496	1,529	1,862	1,369	1,483	1,801	2,031	2,077	2,044	2,305	2,433	1,518	1,389	1,950	1,688	1,786	1,420	1,595	1,570	1,248	1,408	1,281	1,215	1,220	1,025
Acquisition costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	119	1,067	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
4,890	4,872	5,512	5,694	4,985	4,875	4,147	8,136	4,406	4,978	4,523	4,523	4,943	5,258	5,721	4,865	5,303	5,071	4,367	5,369	6,538	6,556	6,793	6,537	5,327	3,387	3,658	3,973	4,891	5,212	4,959	5,707	6,263	6,385	6,823	6,246	5,563	5,171	4,464
Loss from operations
-4,765	-4,747	-5,387	-5,569	-4,860	-4,750	-4,022	-8,011	-4,281	-4,853	-4,398	-4,398	-4,818	-5,133	-5,596	-4,740	-5,178	-4,946	-4,242	-5,244	-6,413	-6,431	-6,668	-6,412	-5,202	-3,262	-3,533	-3,848	-4,766	-5,212	-4,959	-5,707	-6,263	-6,385	-6,823	-6,246	-3,563	-5,171	-4,464
Other income (expense):
(Loss) gain from change in valuation of earn-out milestone liability
-41	101	85	-127	3,130	63	4,114	-277	-270	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments
-	0	0	0	-400	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of in-process research and development
-	-	-	-	-	-	4,510	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Loss) gain from change in valuation of earn-out milestone liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	282	-69	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from valuation of common stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-18	-43	123	96	-18	3	-50	-518	4,380	4,280	-2,866	-881	-447	77	-	375	-586	-	-	-
(Loss) gain from valuation of common stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	123	96	-18	3	-50	-518	4,380	4,280	-2,866	-881	-447	77	-	375	-586	-	-	-
Gain from change in valuation of earn-out milestone liability
-	-	-	-	-	-	-	-	-	-	1,246	1,246	-283	-	-662	408	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from change in valuation of earn-out milestone liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-302	-	-	-	-172	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of in-process research and development
-	-	-	-	-	-	-	-	-	-	2,520	2,520	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment income
88	68	174	144	113	99	106	73	73	23	0	0	1	5	8	4	9	14	15	16	16	19	26	23	7	-	144	-	-	-	-	-	-	-	-	-	-	-	-
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Gain from valuation of common stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	168	453	1,828
Investment income, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	67	16	-	-5	62	5	147	26	0	0	8	13
Interest expense
339	343	349	349	350	-	345	15	-	29	0	0	62	114	161	203	244	281	322	360	392	413	418	263	230	395	162	176	180	171	171	10	5	7	13	111	369	7	8
Other income
1	2	0	-2	0	-0	0	-0	0	-0	0	0	2	1	2	0	-0	-0	-1	0	-0	-	21	-2	-	-	-0	-1	-	-	-	-1	-	-	42	-	-	-	-
Total other income (expense), net
-290	-171	-89	-334	2,493	-188	-634	-219	-195	954	-1,273	-1,273	-341	-262	-813	209	-537	-566	-25	-430	-591	-24	-273	-260	-220	-687	-537	4,269	4,115	-3,047	-1,058	-396	77	264	430	-698	-200	454	1,834
Net loss
-5,056	-3,102	-5,476	-5,904	-2,367	5,480	-4,656	-8,230	-4,476	-3,899	-5,671	-5,671	-5,160	-	-6,409	-4,530	-	-	-	-	-	-	-	-	-	-	-4,071	420	-	-8,259	-6,017	-6,104	-6,186	-	-6,392	-6,944	-3,764	-4,717	-2,630
Deemed dividend related to warrant modification
-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss attributable to common shareholders
-	-	-	-	-	-	-	-	-	-	-5,671	-5,671	-	-5,396	-6,409	-4,530	-5,716	-5,513	-4,267	-5,674	-7,005	-6,455	-6,942	-6,673	-5,422	-3,949	-4,071	420	-5,252	-8,259	-6,017	-6,104	-6,186	-	-	-	-	-	-
Net loss per common share - Basic and diluted
-0.20	-0.11	-0.25	-0.29	-0.12	0.29	-0.26	-0.46	-0.25	1.77	-0.70	-0.70	-3.09	-5.80	-3.22	-2.63	-0.24	-0.22	-0.19	-0.27	-0.35	-0.27	-0.40	-0.38	-0.33	-0.13	-0.30	0.03	-0.55	-	-0.80	-	-0.19	-4.05	-0.25	-0.42	-0.28	-0.38	-0.22
Weighted average common shares outstanding - Basic and diluted
25,804	25,958	21,662	20,605	19,104	17,103	17,801	17,743	17,683	12,728	8,054	8,054	1,670	-19,688	1,993	1,723	23,388	23,269	23,023	20,969	19,990	22,465	17,526	17,526	16,371	-	13,601	-	9,554	-	7,475	-	33,197	-	25,150	16,366	-	-	-
Basic (in Dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.18	-	-	-	-	-	-	-
Diluted (in Dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.18	-	-	-	-	-	-	-
Basic (in Shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,087	-	-	-	33,236	-	-	-	-	-	-	-
Diluted (in Shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,617	-	-	-	33,236	-	-	-	-	-	-	-
Weighted average shares outstanding - basic and diluted (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,452	12,340	-